Quantcast
Last updated on April 19, 2014 at 17:21 EDT

Latest NKT Therapeutics Inc. Stories

2013-12-09 12:25:49

- Preclinical Research with Novel, Highly Specific Mouse anti-iNKT Antibodies Presented at American Society of Hematology Meeting WALTHAM, Mass., Dec. 9, 2013 /PRNewswire/ -- NKT Therapeutics (NKTT) today presented research results with NKT14 and NKT14m, monoclonal antibodies designed to deplete (NKT14) or activate (NKT14m) murine iNKT cells. The results from these studies demonstrate that NKT14 can produce a complete and long lasting depletion of both peripheral blood and tissue...

2013-12-07 12:20:46

-- Complete Peripheral Depletion of iNKT Cells Observed WALTHAM, Mass., Dec. 7, 2013 /PRNewswire/ -- NKT Therapeutics today announced the presentation of initial clinical results with NKTT120, a monoclonal antibody designed to suppress the chronic inflammation associated with sickle cell disease (SCD) pathology. Interim results from an ongoing Phase 1 safety and dose escalation study of NKTT120 in adults with stable SCD demonstrated the intended complete and specific depletion of...

2012-12-06 08:27:09

WALTHAM, Mass., Dec. 6, 2012 /PRNewswire/ -- NKT Therapeutics, Inc., a privately held biotechnology company, announced preclinical study results supporting the potential of its lead therapeutic candidate, NKTT120, as an innovative approach to the treatment of sickle cell disease. Preclinical studies of NKTT120, a humanized monoclonal antibody, showed its ability to generate a safe, rapid, specific and complete depletion of invariant Natural Killer T cells (iNKT cells) 24 hours post dosing,...

2011-02-08 01:00:00

PARSIPPANY, N.J., Feb. 8, 2011 /PRNewswire/ -- DSM Biologics, a business unit of DSM Pharmaceutical Products, today announced the signing of a contract with NKT Therapeutics, Inc. based in Waltham, Mass, USA, the biotechnology company that focuses on developing therapeutics based on unique immune cells called natural killer T (NKT) cells. The contract covers the process development and cGMP manufacturing by DSM of their lead product iNKT mAb. NKT cells are a central part of the human...

2009-10-21 05:00:00

PRINCETON, N.J. and WALTHAM, Mass., Oct. 21 /PRNewswire/ -- BioWa, Inc. (BioWa) and NKT Therapeutics, Inc. (NKTT), announced today that they have entered into an agreement which provides NKTT with access to BioWa's patented POTELLIGENT(®) Technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies. The agreement grants NKTT non-exclusive rights to research, develop, manufacture and commercialize antibodies targeting...

2009-09-01 07:50:00

GENEVA, Sept. 1 /PRNewswire/ -- Selexis SA ("Selexis") and NKT Therapeutics, Inc. ("NKTT") announce today that they have entered into a research services agreement whereby Selexis will screen antibody variants and generate high performance CHO-based production cell lines using their novel platform named INTEGRA-D2M(TM). The Selexis INTEGRA-D2M(TM) platform enables the rapid isolation of production cell lines concomitant with the selection of lead compounds from libraries of protein variants...